ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. von Minckwitz on Lessons Learned From Neoadjuvant Trials in Breast Cancer

Gunter von Minckwitz, MD
Published: Sunday, Mar 13, 2016



Gunter von Minckwitz, MD, director of the German Breast Group Research Institute, discusses lessons learned from clinical trials examining neoadjuvant therapies in patients with breast cancer.

More research needs to be conducted to understand the optimal use of neoadjuvant therapy, von Minckwitz explains. Biomarkers have been developed in order to determine response to treatment, as well as serve as predictive markers of pathologic complete response rates and poor predictive markers of outcomes.

Additionally, researchers can develop findings from a correlative marker in the neoadjuvant setting that can be then confirmed to the adjuvant setting.

<<< View more from the 33rd Annual Miami Breast Cancer Conference



Gunter von Minckwitz, MD, director of the German Breast Group Research Institute, discusses lessons learned from clinical trials examining neoadjuvant therapies in patients with breast cancer.

More research needs to be conducted to understand the optimal use of neoadjuvant therapy, von Minckwitz explains. Biomarkers have been developed in order to determine response to treatment, as well as serve as predictive markers of pathologic complete response rates and poor predictive markers of outcomes.

Additionally, researchers can develop findings from a correlative marker in the neoadjuvant setting that can be then confirmed to the adjuvant setting.

<<< View more from the 33rd Annual Miami Breast Cancer Conference


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x